NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) — The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Weibo Corporation (“Weibo”) (NASDAQ:WB) securities between April 27, 2017 and June 22, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/weibo-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Weibo lacks a requisite internet audio/video program transmission license; and (2) Weibo was posting certain programs with content in violation of Chinese government regulations on its site. On June 22, 2017, Weibo announced receipt of a notice from The State Administration of Press, Publication, Radio, Film and Television of the People’s Republic of China (the “SAPPRFT”). The notice requests that local authorities “take measures to suspend several companies’ video and audio services due to their lacking of an internet audio/video program transmission license and posting of certain commentary programs with content in violation of government regulations on their sites.”
If you suffered a loss in Weibo you have until August 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/weibo-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
Latest posts by Nasdaq NewsFeed (see all)
- Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) - September 20, 2017
- Bone Therapeutics SA : announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis - September 20, 2017
- Sif- Smulders joint venture to engineer and manufacture all monopiles and transition pieces for the Triton Knoll Offshore Windfarm - September 20, 2017